Short-Term Clinical and Oncological Outcome of Prolonging Operation Interval After Neoadjuvant Chemoradiotherapy for Locally Advanced Middle and Low Rectal Cancer

Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research

Related Links:

ConclusionRadiomics of pretreatment MRIs can predict pCR, TRG, and NAR score in patients with LARC undergoing neoadjuvant treatment and TME with moderate accuracy despite extremely heterogenous image data. Both the tumor and MC contain important prognostic information.Key Points• Machine learning of rectal cancer on images from the pretreatment MRI can predict important patient outcomes with moderate accuracy.• The tumor and the tissue around it both contain important prognostic information.
Source: European Radiology - Category: Radiology Source Type: research
Condition:   Locally Advanced Rectal Cancer Interventions:   Drug: PD-1 antibody;   Drug: Capecitabine;   Drug: Irinotecan;   Radiation: Neoadjuvant Radiotherapy Sponsor:   Fudan University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Locally Advanced Rectal Cancer Interventions:   Drug: PD-1 antibody;   Drug: Capecitabine;   Drug: Irinotecan;   Radiation: Neoadjuvant Radiotherapy Sponsor:   Fudan University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Locally Advanced Rectal Cancer Interventions:   Drug: PD-1 antibody;   Drug: Capecitabine;   Drug: Irinotecan;   Radiation: Neoadjuvant Radiotherapy Sponsor:   Fudan University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Locally Advanced Rectal Cancer Interventions:   Drug: PD-1 antibody;   Drug: Capecitabine;   Drug: Irinotecan;   Radiation: Neoadjuvant Radiotherapy Sponsor:   Fudan University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Locally Advanced Rectal Cancer Interventions:   Drug: PD-1 antibody;   Drug: Capecitabine;   Drug: Irinotecan;   Radiation: Neoadjuvant Radiotherapy Sponsor:   Fudan University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Locally Advanced Rectal Cancer Interventions:   Drug: PD-1 antibody;   Drug: Capecitabine;   Drug: Irinotecan;   Radiation: Neoadjuvant Radiotherapy Sponsor:   Fudan University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Locally Advanced Rectal Cancer Interventions:   Drug: PD-1 antibody;   Drug: Capecitabine;   Drug: Irinotecan;   Radiation: Neoadjuvant Radiotherapy Sponsor:   Fudan University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Locally Advanced Rectal Cancer Interventions:   Drug: PD-1 antibody;   Drug: Capecitabine;   Drug: Irinotecan;   Radiation: Neoadjuvant Radiotherapy Sponsor:   Fudan University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
This article will make a further study on this point. Methods: We collected perioperative clinical data from 382 patients with rectal cancer who underwent surgery from September 2015 to May 2017. After 1 month of follow-up, relevant risk factor data were collected and analyzed. Results: Data analysis showed that the incidence of AL was 14.65%. In single factor analysis, patients with high score of NRS-2002, high score of PG-SGA, diabetes, perioperative blood transfusion, postoperative diarrhea, later tumor stage, high score of ASA, low postoperative albumin, and rectal cancer patients with tumor close to the anus...
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
More News: Cancer | Cancer & Oncology | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Rectal Cancers